NCT02086786View on ClinicalTrials.gov

Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Schizophrenia
Interventions
DRUG

Risperidone ISM

"Four doses of 75 mg of Risperidone ISM as intramuscular (IM) injection into the deltoid muscle at 28-day intervals.~Four doses of 75 mg of Risperidone ISM as intramuscular injections into the gluteal muscle at 28-day intervals."

Trial Locations (1)

63141

St Louis Clinical Trials, LC, St Louis

All Listed Sponsors
lead

Rovi Pharmaceuticals Laboratories

INDUSTRY

NCT02086786 - Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia | Biotech Hunter | Biotech Hunter